Chemistry:Tinengotinib
From HandWiki
Tinengotinib is an investigational new drug that is being evaluated for the treatment of cancer.[1]
It is an multi-kinase inhibitor designed to target a range of kinases involved in cancer cell proliferation, angiogenesis, and immune response modulation. Specifically, it inhibits fibroblast growth factor receptors (FGFRs) 1–3, janus kinase (JAK) 1/2, vascular endothelial growth factor receptors (VEGFRs), and aurora kinases A/B.[2]
References
- ↑ "Tinengotinib - TransThera Biosciences". AdisInsigh. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800051801.
- ↑ "Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer". Molecular Cancer Therapeutics 22 (2): 205–214. February 2023. doi:10.1158/1535-7163.MCT-22-0012. PMID 36223547.
 |  |
